Recently, antibodies targeting the programmed cell death-1 (PD-1) pathway have been widely used in numerous combination regimens to improve the tumour response and prolong the overall survival (OS) of HCC patients. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.